In-market Utilisation of Liraglutide Used for Weight Management in Europe
In-market Utilisation of Liraglutide Used for Weight Management in Europe: a Retrospective Medical Record Review Study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Bad Nauheim, Germany, 61231
- Novo Nordisk Investigational Site
-
Bünde, Germany, 32257
- Novo Nordisk Investigational Site
-
Essen, Germany, 45147
- Novo Nordisk Investigational Site
-
Hamburg, Germany, 20097
- Novo Nordisk Investigational Site
-
Kaiserslautern, Germany, 67655
- Novo Nordisk Investigational Site
-
Mainz, Germany, 55124
- Novo Nordisk Investigational Site
-
München, Germany, 81477
- Novo Nordisk Investigational Site
-
Münster, Germany, 48143
- Novo Nordisk Investigational Site
-
Ulm, Germany, 89073
- Novo Nordisk Investigational Site
-
-
-
-
-
Catania, Italy, 95122
- Novo Nordisk Investigational Site
-
Chieti, Italy, 66100
- Novo Nordisk Investigational Site
-
Cremona, Italy, 26900
- Novo Nordisk Investigational Site
-
Novara, Italy, 28100
- Novo Nordisk Investigational Site
-
Pisa, Italy, 56126
- Novo Nordisk Investigational Site
-
Potenza, Italy, 85100
- Novo Nordisk Investigational Site
-
Roma, Italy, 00128
- Novo Nordisk Investigational Site
-
Rome, Italy, 00168
- Novo Nordisk Investigational Site
-
Rome, Italy, 161
- Novo Nordisk Investigational Site
-
Siena, Italy, 53100
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Initiation of liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg (initiation is defined as no prescription of the same brand within the previous 12 months)
- Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability of the study
Exclusion Criteria:
-Patients or physicians who previously participated in interventional studies for liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg will not be eligible to participate in the study -For the full study, sites and patients included in the pilot will be excluded
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg
|
Patients will be treated according to routine clinical practice at the discretion of the treating physician.
The study will gather data over the course of routine treatment for liraglutide 3.0 mg and liraglutide 1.2 mg/1.8 mg treated patients
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with BMI above or equal to 30 kg/m^2
Time Frame: Less than 6 months before date of first prescription
|
Less than 6 months before date of first prescription
|
|
|
Number of patients with BMI above or equal to 27kg/m^2 and below 30 kg/m^2 and 1 or more comorbidity
Time Frame: Less than 6 months before date of first prescription
|
Dysglycaemia (Type 2 Diabetes Mellitus [T2DM] or prediabetes), hypertension, dyslipidaemia, obstructive sleep apnoea, and/or other weight-related comorbidities
|
Less than 6 months before date of first prescription
|
|
Number of patients with above or equal to 27 kg/m^2 and below 30 kg/m^2 and no comorbidities
Time Frame: Less than 6 months before date of first prescription
|
Dysglycaemia (Type 2 Diabetes Mellitus [T2DM] or prediabetes), hypertension, dyslipidaemia, obstructive sleep apnoea, and/or other weight-related comorbidities.
|
Less than 6 months before date of first prescription
|
|
Number of patients with BMI below 27 kg/m^2
Time Frame: Less than 6 months before date of first prescription
|
Less than 6 months before date of first prescription
|
|
|
Number of patients with BMI not measured
Time Frame: Within 6 months before date of the first prescription
|
Within 6 months before date of the first prescription
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with liraglutide 1.2 or 1.8 mg prescriptions with dose information of 3.0 mg per day
Time Frame: From date of first prescription until 24 months
|
From date of first prescription until 24 months
|
|
|
Number of patients with liraglutide 1.2 or 1.8 mg prescriptions and indication of weight management
Time Frame: From date of first prescription until 24 months
|
From date of first prescription until 24 months
|
|
|
Number of patients with liraglutide 3.0 mg prescriptions who have reached a dose of 3.0 mg
Time Frame: By 12 weeks after first prescription date
|
While adhering to the dose escalation according to label
|
By 12 weeks after first prescription date
|
|
Number of patients with liraglutide 3.0 mg prescriptions and other GLP-1 receptor agonists prescribed during continued treatment with liraglutide 3.0 mg
Time Frame: From date of first prescription until 24 months
|
Number of patients
|
From date of first prescription until 24 months
|
|
Number of patients with continued treatment with liraglutide 3.0 mg
Time Frame: From date of first prescription until 0-6 weeks; 7-12 weeks; 13-18 weeks; 19-24 months
|
Number of patients
|
From date of first prescription until 0-6 weeks; 7-12 weeks; 13-18 weeks; 19-24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NN8022-4241
- U1111-1185-3661 (Other Identifier: WHO)
- EUPAS16225 (Registry Identifier: EU PAS Register)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.